Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United Kingdom

Originally published on Bristol Myers Squibb Newsroom

PRINCETON, NJ / ACCESSWIRE / March 29, 2024 / Bristol Myers Squibb (NYSE: BMY) unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom. The new health equity grants are an extension of the company's broader long-term commitment to invest $150M in health equity by 2025.

Inequities in healthcare systems present a unique global challenge, with some studies suggesting that SDoH factors account for up to 50% of health outcomes within the United States.¹ The World Health Organization (WHO) defines SDoH as non-medical factors that influence health outcomes, such as: income and social status, education, physical environment, social support networks, genetics, health services and gender. As echoed by the United Nations Sustainable Development Goal #3 (Good Health & Well-being), SDoH are crucial to ensure healthy lives and promote well-being for all at all ages.²

"We know that a healthier world is attainable, but access remains a significant challenge for many patients and social determinants of health present barriers to people attaining their full potential for health and well-being," said Cari Gallman, Executive Vice President, Corporate Affairs, Bristol Myers Squibb. "These new health equity grants reinforce Bristol Myers Squibb's commitment to ensuring all patients have access to high-quality health care, regardless of where they live."

These healthcare-strengthening grants will support eight organizations that are addressing the root causes of inequities in an effort to deliver long-lasting impacts at a community level. The grantees were selected in countries with underserved communities living with cancer and blood disorders. Based on the outcomes of this pilot program, the Company will consider expansion to other geographies and communities to remove systemic barriers to care, and enable better access and health outcomes. The grantees include:

• The Instituto Lado a Lado pela Vida in Brazil, which serves the rural population and patients with cancer who live in the countryside and small, economically disadvantaged towns of the North area of Minas Gerais. This project focuses on prevention, improvement of diagnosis and patient referral for treatment.
• The Instituto Oncoguia in Brazil, which is focusing on training the health team at Sistema Único de Saúde Oncology Centers with the aim of ensuring that all non-medical professionals who care for people with cancer are informed and empowered with the latest information in the world of cancer.
• The Gabriel Project Mumbai in India, which is creating innovative and comprehensive solutions to treat sickle cell anemia and oral cancer among underserved tribal villages.
• The Liver Foundation, West Bengal in India, which is training rural healthcare providers to be advocates, referral points and drop-out counselors at the grassroot level and align them with public health linkages for prevention of hepatocellular carcinoma in the rural Indian communities.
• The Foundation for Education and Development in Thailand, which is working to improve prevention and primary care in Burmese migrant communities living close to the southern border with Myanmar. It aims to do this by increasing linkages of migrants to Thai healthcare facilities and services to increase healthcare access for Myanmar migrants.
• The Patients Association in the United Kingdom, which aims to bridge the gap between social care and healthcare, ultimately reducing health disparities and improving access to quality care for underserved populations.
• Blood Cancer UK in the United Kingdom, which is leading a project aimed at reducing inequality in clinical trial recruitment for people from ethnic minority communities with blood cancer. Blood Cancer UK is also partnering with local communities to co-design a model, with accompanying tools, campaigns or services, to improve awareness of and enrollment in clinical trials at a local level.
• The Less Survivable Cancer Taskforce in the United Kingdom through Pancreatic Cancer UK, which is working to ensure governments and health services across the UK prioritize and commit to concrete actions for less survivable cancers, with the goal of doubling survival rates over the next decade.

Bristol Myers Squibb's Approach to Health Equity

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 44,02$, was einem Rückgang von -1,86% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Vontobel

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer